Annexon Announces Proposed Public Offering of Common Stock

Core Viewpoint - Annexon, Inc. has initiated an underwritten public offering of $125 million in common stock, with an additional option for underwriters to purchase up to $18.75 million more, aimed at advancing its clinical platform for neuroinflammatory diseases [1][2]. Company Overview - Annexon is a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye [5]. - The company targets upstream C1q to inhibit the classical complement inflammatory cascade, with therapeutic candidates showing promise in conditions such as Guillain-Barré syndrome, Huntington's disease, and geographic atrophy [5]. Offering Details - The public offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on April 1, 2024 [3]. - The offering will be made through a prospectus supplement and accompanying prospectus, which will be available on the SEC's website [3]. Underwriters - The joint book-running managers for the offering include J.P. Morgan, Jefferies, TD Cowen, BofA Securities, and Wells Fargo Securities [2].